EW
Edwards Lifesciences Corporation
NYSE · Healthcare · Medical - Devices · US
$89.71
−0.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.5B | 6.1B | 5.4B | 5.0B | 5.4B |
| Cost of Revenue | 1.4B | 1.3B | 1.1B | 1.0B | 1.2B |
| Gross Profit | 5.1B | 4.7B | 4.3B | 4.0B | 4.2B |
| Operating Expenses | |||||
| R&D Expense | 1.1B | 1.1B | 1.1B | 962.9M | 945.2M |
| SG&A Expense | 2.2B | 2.1B | 1.8B | 1.6B | 1.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (42.8M) | (59.9M) | 101.1M | — | — |
| Total Operating Expenses | 3.2B | 3.1B | 2.9B | 2.5B | 2.5B |
| Cost and Expenses | 4.7B | 4.4B | 4.1B | 3.6B | 3.7B |
| Operating Income (EBIT) | 1.8B | 1.6B | 1.4B | 1.4B | 1.7B |
| Non-Operating | |||||
| Interest Income | 138.0M | 148.4M | 120.3M | 67.2M | 35.5M |
| Interest Expense | — | — | 19.8M | 17.6M | 26.2M |
| Net Interest Income | 138.0M | 148.4M | 100.5M | 49.6M | 9.3M |
| Other Non-Op Income/Expense | (412.0M) | (363.3M) | 169.4M | (54.9M) | 65.0M |
| Non-Operating Income (excl Interest) | 412.3M | 363.3M | (189.2M) | 37.3M | (91.2M) |
| EBT (Pre-Tax Income) | 1.4B | 1.3B | 1.5B | 1.4B | 1.8B |
| Income Tax Expense | 439.0M | 216.9M | 152.1M | 152.4M | 245.5M |
| Bottom Line | |||||
| Net Income | 1.0B | 1.1B | 4.2B | 1.4B | 1.5B |
| Earnings from Cont. Ops | 978.6M | 1.1B | 1.4B | 1.2B | 1.5B |
| Earnings from Discont. Ops | 25.0M | 13.4M | 2.8B | 179.4M | — |
| Bottom Line Net Income | 1.0B | 1.1B | 4.2B | 1.4B | 1.5B |
| Per Share | |||||
| Basic EPS | $1.74 | $1.84 | $6.98 | $2.31 | $2.46 |
| Diluted EPS | $1.74 | $1.83 | $6.97 | $2.30 | $2.44 |
| Revenue Per Share | $11.30 | $10.38 | $9.10 | $8.26 | $8.70 |
| Shares | |||||
| Basic Shares Outstanding | 576.4M | 584.8M | 597.7M | 606.7M | 619.0M |
| Diluted Shares Outstanding | 577.6M | 585.8M | 599.3M | 609.4M | 624.2M |
| Profitability Metrics | |||||
| EBITDA | 1.5B | 1.4B | 1.7B | 1.5B | 2.0B |
| D&A | 122.8M | 156.6M | 155.2M | 144.9M | 166.8M |
| EBIT | 1.4B | 1.3B | 1.6B | 1.4B | 1.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026